E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Nervous System Diseases [C10] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 16.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10001064 |
E.1.2 | Term | Acute schizophrenia |
E.1.2 | System Organ Class | 100000004873 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
evaluate the efficacy of lurasidone (40 mg/day and 80 mg/day) compared with placebo in adolescent subjects with schizophrenia (diagnosed by Diagnostic and Statistical Manual of Mental Disorders, 4th Ed., Text Revision [DSM-IV-TR] criteria) as measured by the change from Baseline in the Positive and Negative Syndrome Scale (PANSS) total score at Week 6. |
|
E.2.2 | Secondary objectives of the trial |
*Change from Baseline in Clinical Global Impression severity (CGI-S) scale score, CDRS-R score, PQ-LES-Q score, Children’s Global Assessment Scale (CGAS) score, and PANSS positive, negative, general psychopathology, cognition score and excitability subscale scores, as compared to placebo
*Proportion of responders where response is based on 20 percent or greater improvement from baseline in PANSS total score at the last observed value
*Proportion of patients achieving remission defined as a score not exceeding 3 (mild severity) for items P1, P2, P3, N1, N6, G5 and G9 of the PANSS
*discontinuation due to AEs, SAEs; frequency and severity of suicidality laboratory parameters , vital signs, physical examinations and ECGs, mean change from for height and body weight, mean changes of BMI and waist circumference, UKU, and cognitive side effects, Tanner staging, hormonal parameters, Movement disorders, suicidality (C-SSRS), patients who discontinued due to AEs
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
. Subjects must provide written informed assent and be willing to participate in the study.
Written informed consent from parent(s) or legal guardian(s) with sufficient intellectual capacity to understand the study and support subjects’ adherence to the study procedures.
2. Male or female subjects 13 to 17 years of age, inclusive.
3. DSM-IV-TR axis I primary diagnosis of schizophrenia (including disorganized (295.10), paranoid (295.30), undifferentiated (295.90) subtypes) and confirmation of the schizophrenia diagnosis by an adequately trained clinician at the time of screening, by means of the Schedule for Affective Disorders and Schizophrenia for School-age Children (K-SADS-PL).
4. In the judgment of the clinician, the subject has an acute exacerbation of psychotic symptoms (no longer than 2 months in duration) and marked deterioration of function from baseline (by history), or, the subject has been hospitalized for the purpose of treating an acute psychotic exacerbation for 2 consecutive weeks or less immediately before screening
5. Willing and able to adhere to protocol-specified meal requirements during dosing.
6. Willing and able to swallow the size and number of lurasidone tablets specified per protocol.
|
|
E.4 | Principal exclusion criteria |
1. Has a history or current diagnosis of mental retardation neurological malignant syndrome or any neurologic disorder or severe head trauma.
2. Evidence of any chronic organic disease of the CNS such as tumors, inflammation, active seizure disorder, vascular disorder, potential CNS related disorders that might occur in childhood– eg, Duchenne Muscular dystrophy, myasthenia gravis, or other neurologic or serious neuromuscular disorders.In addition, subjects must not have a history of persistent neurological symptoms attributable to serious head injury. Past history of febrile seizure, drug-induced seizure of alcohol withdrawal seizure is not exclusionary
3. A history of electroconvulsive therapy (ECT).
4. Exhibits evidence of moderate or severe extrapyramidal symptoms, dystonia, tardive dyskinesia, or any other moderate or severe movement disorder. Severity to be determined by the investigator.
5. Clinically significant neurological, metabolic (including type 1 diabetes), hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, carcinoma, and/or urological disorder that would pose a risk to the subjects if they were to participate in the study or that might confound the results of the study.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
evaluate the efficacy of lurasidone (40 mg/day and 80 mg/day) compared with placebo in adolescent subjects with schizophrenia |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
•Change from Baseline in Clinical Global Impression severity (CGI-S) scale score, as compared to placebo
•Change from Baseline in PANSS positive, negative, general psychopathology, cognition score and excitability subscale scores
•CDRS-R score
•Proportion of responders where response is based on 20 percent or greater improvement from baseline in PANSS total score at the last observed value
•PQ-LES-Q score
•Children’s Global Assessment Scale (CGAS) score
•Proportion of patients achieving remission defined as a score not exceeding 3 (mild severity) for items P1, P2, P3, N1, N6, G5 and G9 of the PANSS
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 3 |
E.8.3 |
Will this trial be conducted at a single site globally?
| No |
E.8.4 | Will this trial be conducted at multiple sites globally? | Yes |
E.8.6 Trial involving sites outside the EEA |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | Specify the countries outside of the EEA in which trial sites are planned |
Bulgaria |
China |
Italy |
Romania |
Colombia |
Korea, Democratic People's Republic of |
Malaysia |
Puerto Rico |
Spain |
Mexico |
Philippines |
Serbia |
Ukraine |
United States |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |